Arvinas, Inc. (ARVN) SEC Filings & Earnings Calls

Clinical-stage biotech with no approved product revenue; reliance on pipeline success and partnership milestones.

“Arvinas is a clinical-stage biotechnology company; no revenue from product sales; cash burn continues.”

Out-licensing of VEPPANU reduces potential upside from direct commercialization but provides near-term cash and reduces risk.

“Entered into a license agreement with Rigel Pharmaceuticals, Inc. for the exclusive global development, manufacturing, and commercialization rights for VEPPANU.” · word for word

Clinical hold on ARV-102 PSP trial

“As a result of the FDA’s request, the planned Phase 1b clinical trial, in which we have not yet dosed any patients, is on clinical hold and will not begin until the FDA completes its review and authorizes initiation of the clinical trial.” · word for word

Dependence on Rigel for VEPPANU revenue

“Our ability to generate revenue from the sale of VEPPANU will be entirely dependent on Rigel's performance of its obligations under the Rigel License Agreement, and we may never generate product revenue from the Rigel License Agreement to realize any profits from the out-license of VEPPANU.” · word for word

Workforce reductions may impact operations

“In April 2025, as part of our decision to streamline operations across our organization and enable the efficient progression of our portfolio, we committed to and approved a reduction of our workforce by approximately 33% across all areas of our company.” · word for word

CMO departure

“In the second quarter of 2026, we announced that Noah Berkowitz, M.D., Ph.D. would depart from his employment with us as chief medical officer effective July 3, 2026.” · word for word

Key executive departure could disrupt clinical development and regulatory strategy.

“CMO departure; search for replacement underway.”

Dependence on Rigel's successful commercialization of VEPPANU.

“whether Rigel will successfully commercialize VEPPANU on the current timeline expectations or at all” · word for word

Pipeline dependency on ARV-806 out-licensing success; no partnered revenue yet.

“The Company plans to seek an out-licensing agreement for any additional clinical trials, including dose expansion or combination clinical trials, for ARV-806.” · word for word

Closing subject to HSR review; milestone payments contingent on future events.

“Closing of the License Agreement transaction is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.” · word for word

Commercial execution risk for VEPPANU under Rigel; pipeline dependency on clinical data.

“License agreement with Rigel transfers commercialization but Arvinas retains development responsibilities.”

Clinical hold on ARV-102 PSP trial

“Following the 30-day review period, the FDA requested final data from our chronic toxicology studies in non-human primates prior to authorizing the initiation of the Phase 1b clinical trial in the U.S. in patients with PSP. As a result, the planned Phase 1b clinical trial, in which we have not yet dosed any patients, is on clinical hold and will not begin un” · word for word

Dependence on third-party commercialization partner for VEPPANU

“We and Pfizer remain on track to announce selection of a third party to commercialize VEPPANU. We expect that all decisions related to pricing, access, reimbursement, and ex-U.S. regulatory plans for VEPPANU will be determined by the selected partner.” · word for word

No product revenue expected in near future

“We do not expect to generate any revenue from product sales in the near future, if ever. While we do have one approved product, VEPPANU, as we announced in September 2025, we and Pfizer have agreed to jointly select a third party for the commercialization and potential further development of VEPPANU. Given this, we do not expect to begin to generate revenue,” · word for word

Need for substantial additional funding

“Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research or product development programs or any future commercialization efforts.” · word for word

Commercialization risk: third-party selection pending

“Company and Pfizer remain on track to announce selection of a third party to commercialize VEPPANU”

Significant stock price decline following VERITAC-2 readout

“In particular, we recognize this outcome occurred in the context of a significant decline in our share price following the VERITAC-2 Phase 3 clinical trial readout from our vepdegestrant program that did not meet investor expectations.” · word for word

Low say-on-pay support (75%)

“At the 2025 annual meeting of stockholders, results on our say-on-pay proposal received support of approximately 75% of the votes cast by stockholders, excluding broker non-votes and abstentions.” · word for word

Clinical trial risk remains; Phase 1 data is early and further studies needed.

“Data from single-center, randomized, double-blind, placebo-controlled, multiple dose cohort; plans for Phase 1b and registrational trial pending regulatory feedback.”

Clinical trial failure risk

“We are a clinical-stage biotechnology company... we have not generated any revenue from product sales.” · word for word

Regulatory approval risk

“Any delay or failure to obtain regulatory approvals would materially adversely affect our product candidate development efforts.” · word for word

Dependence on vepdegestrant

“Vepdegestrant is our most advanced product candidate... the FDA has accepted our NDA.”

Need for additional funding

“We will need to obtain substantial additional funding in connection with our continuing operations.” · word for word

Clinical-stage company with no approved products at time of filing.

“Clinical-stage biotechnology company; revenue generation still dependent on pipeline success.”

Leadership transition risk; new CEO has no prior CEO experience.

“Randy Teel previously served as Chief Business Officer and interim CFO.”

Preclinical data may not translate to clinical success; early stage.

“preclinical data ... may not be indicative of clinical outcomes”

No revenue; reliance on pipeline success and partnership.

“Clinical-stage company with no approved products; all revenue potential depends on regulatory and clinical outcomes.”

Dependence on vepdegestrant approval and commercialization

“We do not expect to generate any revenue from product sales in the near future, if ever.” · word for word

Need for substantial additional funding

“We will need to obtain substantial additional funding in connection with our continuing operations.” · word for word

Clinical trial and regulatory uncertainty

“The successful development and commercialization of our product candidates is highly uncertain.” · word for word

Competition from other therapies

“effectively competing with other therapies.” · word for word

Reliance on collaboration partners (Pfizer, Novartis)

“Pfizer may terminate the Vepdegestrant (ARV-471) Collaboration Agreement for convenience” · word for word

Preclinical data may not predict clinical outcomes.

“Forward-looking statements caution about risks.”